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Polycystic ovary syndrome is a highly frequent reproductive-endocrine disorder affecting up to 8–10% of women worldwide at
reproductive age. Although its etiology is not fully understood, evidence suggests that insulin resistance, with or without
compensatory hyperinsulinemia, and hyperandrogenism are very common features of the polycystic ovary syndrome phenotype.
Dysfunctional white adipose tissue has been identified as a major contributing factor for insulin resistance in polycystic ovary
syndrome. Environmental (e.g., chronodisruption) and genetic/epigenetic factors may also play relevant roles in syndrome
development. Overweight and/or obesity are very common in women with polycystic ovary syndrome, thus suggesting that
some polycystic ovary syndrome and metabolic syndrome female phenotypes share common characteristics. Sleep disturbances
have been reported to double in women with PCOS and obstructive sleep apnea is a common feature in polycystic ovary
syndrome patients. Maturation of the luteinizing hormone-releasing hormone secretion pattern in girls in puberty is closely
related to changes in the sleep-wake cycle and could have relevance in the pathogenesis of polycystic ovary syndrome. This
review article focuses on two main issues in the polycystic ovary syndrome-metabolic syndrome phenotype development: (a) the
impact of androgen excess on white adipose tissue function and (b) the possible efficacy of adjuvant melatonin therapy to
improve the chronobiologic profile in polycystic ovary syndrome-metabolic syndrome individuals. Genetic variants in melatonin
receptor have been linked to increased risk of developing polycystic ovary syndrome, to impairments in insulin secretion, and to
increased fasting glucose levels. Melatonin therapy may protect against several metabolic syndrome comorbidities in polycystic
ovary syndrome and could be applied from the initial phases of patients’ treatment.
1. Introduction
Polycystic ovary syndrome (PCOS) is a highly frequent
reproductive-endocrine disorder detected in up to 8–10% of
women at reproductive age worldwide. Due to its heteroge-
neous nature, different criteria have been established in the
course of several years in order to lead to a more precise
PCOS diagnosis [1–5]. Presently, accepted criteria indicate
that PCOS patients are characterized by oligomenorrhea or
amenorrhea, hyperandrogenism, and/or hyperandrogen-
emia, with enlarged ovary volume full of cystic ultrasound
images [1].
Although the etiology of PCOS is not fully understood,
evidence suggests that insulin resistance (IR), with or without
compensatory hyperinsulinemia, contributes to inhibit liver
sex hormone-binding globulin (SHBG) production and to
stimulate ovarian/adrenal androgen secretion. Dysfunctional
white adipose tissue (WAT) has been identified as a major
contributing factor for IR in PCOS. Environmental and
genetic/epigenetic factors may also play relevant roles in
PCOS development [6, 7].
The dysmetabolic aspect of PCOS has recently gained
much attention. Several features of metabolic disturbances,
particularly IR and hyperinsulinemia, have been observed
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in most women with PCOS [8]. Therefore, overweight and/or
obesity (specifically, enlarged visceral fat) are very common
in women with PCOS, thus indicating that some PCOS and
metabolic syndrome (MS) female phenotypes share common
characteristics [9].
MS is a cluster of endocrine-metabolic dysfunctions
including IR, overweight/central obesity, dyslipidemia,
hypertension, and high risk of cardiovascular disease [10].
In this regard, studies confirm that MS is more common
among PCOS patients due to the higher prevalence of IR
and hyperadiposity (visceral) in these women [11, 12]. More-
over, PCOS patients have an elevated risk of MS [12], indicat-
ing that WAT dysfunction is a highly prevalent and common
feature in the PCOS-MS phenotype [4, 13].
Although not yet deeply investigated, sleep disturbances
have been reported to double in women with PCOS. Indeed,
PCOS patients displayed increased difficulty in falling to
sleep and staying asleep [14], with excessive daytime somno-
lence being higher in sleep-disordered than in not sleep-
disordered PCOS women [15]. In this regard, obstructive
sleep apnea is a common feature in adult [16] and adolescent
[17] PCOS patients suffering multiple comorbidities, such as
IR and hyperadiposity. Significant chronodisruption occurs
in patients suffering from obstructive sleep apnea as
evidenced by a disrupted melatonin circadian rhythm [18].
A clear relationship between sleep disturbances and repro-
ductive dysfunction has also been noticed in non-PCOS
women: those sleeping less than 6h daily have shorter or
longer menstrual cycles [19].
Experiments using neonatally androgenized female rats
(the Barraclough PCOS model) indicated an altered pattern
of hypothalamic luteinizing hormone-releasing hormone
(LHRH) and pituitary LH/FSH contents directly related to
changes in the pulsatile pattern of LH/FSH release [20]. In
this regard, maturation of the LHRH secretion pattern in
girls across puberty has been reported to be closely related
to changes in the sleep-wake cycle and is suggested to be
relevant in the pathogenesis of PCOS [21].
Overall metabolic-reproductive-cardiovascular risk asso-
ciated with PCOS urges for a more broadly specific therapeu-
tic approach in medical care of PCOS patients. This short
review article focuses on two main issues in PCOS-MS phe-
notype development: (a) the impact of androgen excess on
WAT function and (b) a possible adjuvant melatonin therapy
to improve the chronobiologic profile in PCOS individuals.
2. Cooperative Effect of Androgens on White
Adipose Tissue Dysfunction
Adipose tissue mass and distribution pattern display clear
gender/sex dimorphism [22, 23]. Whereas men have greater
predisposition to accumulate visceral adipose tissue (VAT)
(known as android distribution) [23], women accumulate
WAT in the gluteofemoral position (known as gynoid distri-
bution) [22]. VATmass expansion is associated with a higher
risk of type 2 diabetes mellitus and cardiovascular disease
[24]. The relationship between blood androgen levels and
WAT function in women seems to be more complex. It is
accepted that androgen excess is associated with central
obesity, although some studies deny this assumption. PCOS
phenotypes often have hyperandrogenemia associated with
IR and accumulate WAT mass [25, 26]. Testosterone is able
to directly induce IR in adipocytes [27], in part by decreasing
cellular glucose uptake [28].
Studies performed on the preadipocyte cell line 3T3-L1
and on multipotent cell lines (C3H10T1/2) indicate that
testosterone inhibits cell proliferation and differentiation to
mature adipocytes [29–31]. A similar inhibitory testosterone
effect is found in human adipocyte precursor cells (APCs)
from distinct WAT pads. It is possible that the antiadipo-
genic action of androgens is due to the inhibiting activity of
PPAR-γ2 and C/EBP-α functions; interestingly, induction
of APCs to differentiate results in increased AR expression
[32]. Moreover, it is widely accepted that inhibition of the
adipogenic process results in hypertrophic WAT mass
expansion due to enlargement of the local adipocyte size
[33]. Thus, in spite of its inhibitory effect on adipogenesis,
it seems feasible that testosterone could induce WAT
(VAT) pad mass expansion by increasing the cell size (hyper-
trophic pad mass expansion). Most studies of androgen
effects on the adipogenic process have focused on the termi-
nal phase of the process, then it remains to be determined
whether testosterone acts on other stages of adipogenesis
(e.g., by influencing APC number and competency).
It must be taken into account that hypertrophy
expansion of WAT mass, as it occurs in an androgen excess
endogenous milieu, is due to the large size of local adipocytes
that release large amounts of proinflammatory adipocyto-
kines [such as leptina (LEP), resistin, tumor necrosis factor
alpha (TNFα), plasminogen activator inhibitor type-1
(PAI-1), interleukin-1 (IL-1), and IL-6, among others].
These substances are highly capable of diminishing tissue
insulin sensitivity and promoting oxidative stress (OS).
Moreover, hypertrophic WAT cells did also release few
amounts of adiponectin (ADIPOQ), an insulin-sensitizing
adipokine, thus worsening local (white adipocyte) and
peripheral tissue insulin sensitivity.
Interestingly, studies in the rodent neonatal androgeniza-
tion model of PCOS clearly showed that early transient
testosterone excess in female rats resulted in an adult
phenotype characterized by several endocrine-metabolic
dysfunctions [34]. Indeed, these rats showed altered WAT
(parametrial tissue-pad) functionality, such as enlarged pad
mass, replete of large (insulin-resistant) adipocytes and
containing very low ADIPOQ protein [34]. Moreover, their
isolated WAT adipocytes did release excess of LEP and
resulted to be highly resistant to insulin-stimulated LEP
secretion [34]. These dysfunctional PCOS rats were peripher-
ally characterized by increased levels of LEP, PAI-1, and non-
esterified fatty acids and decreased ADIPOQ concentration
[34]. Their responses to an ip glucose tolerance test indicated
(by analyzing the area under the curve values) that although
they were still fully able to manage glycemias (normal glucose
tolerance), this occurred at the expenses of compensatory
hyperinsulinemias, whereas adiponectinemias remained very
low [34]. Some of these altered functions are shown in
Figure 1. The alterations indicate that a phenotype shifted
towards an overall state of IR and inflammation. Relevantly,
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neonatal treatment with flutamide, a nonsteroidal antago-
nist of the androgen receptor, induced a decrease in the
peripheral levels of leptin [35]. Collectively, these data
indicate that early treatment with testosterone increases
susceptibility to MS [36] development and, conversely,
that flutamide treatment improves this condition. These
observations strongly support that testosterone exerts spe-
cific receptor-mediated effects [37], the androgen receptor
being expressed in both white adipocytes and APCs [38].
However, the level of androgen receptor expression differs
among WAT depots. VAT has higher receptor expression
levels than subcutaneous fat deposits [32, 38, 39], which
could explain in part the differential actions of testosterone
on different adipose tissue depots.
Altered lipolysis/lipogenesis balance contributes to the
increase in lipid storage in adipose cells and therefore to the
development of unhealthy (hypertrophic) VAT mass expan-
sion. As mentioned above, androgen excess is per se a clear
inducing factor of white adipocyte hypertrophy, and these
cells overproduce (enhanced synthesis and secretion) proin-
flammatory adipokines (including angiotensinogen and free
fatty acids), resulting in a local inflammatory state. Large
adipocytes are indeed insulin-resistant (IR) and character-
ized by high cell reticulum endoplasmic oxidative stress
(REOS) content, enhanced lipolytic activity, cell hypoxia,
and apoptosis. Moreover, large IR adipocytes are not well
recognized by the immune system, and, as a consequence,
macrophages react against to and infiltrate dysfunctional
WAT, thus worsening the inflammatory state. These
alterations in PCOS women, in turn, affect multiple organ
functions, namely, at liver [40], muscle [41], endocrine
pancreas [42], and endothelium [43] levels, thus compromis-
ing cardiovascular function (hypertension and atherogene-
sis) [44] (Figure 2).
Regarding ovarian function, recent studies from one of
our laboratories using the PCOS rat phenotype indicated a
clear ovary dysfunctional folliculogenesis [45] as indicated
by the number of secondary and atretic stage follicles; indeed,
a 3-fold lower number and a 5-fold higher number, respec-
tively, were noticed in the PCOS rat phenotype than in the
normal rat (Figure 3(a)). Moreover, ovary images in normal
animals fully correspond with expected characteristics (e.g.,
antral cavity, corpus luteum, oocyte, granulosa cells, and
internal and external theca cells) (Figure 3(b)), whereas those
from PCOS rats displayed dysfunctional characteristics
compatible with a large antral cavity in a cystic follicle and
showed decreased granulosa and theca (internal and
external) cell layers (Figure 3(b)). This misprogramming in
carbohydrate metabolism and dyslipidemia (e.g., a predia-
betic state) as well as the inflammatory state indicate that
the PCOS rat phenotype is highly prone to developing
cardiovascular disease and reproductive dysfunction (abnor-
mal folliculogenesis). Therefore, subfertility/infertility and/or
poor pregnancy outcome (early abortion and/or preeclamp-
sia) could ensue.
3. Chronobiology in PCOS
As mentioned, some PCOS phenotypes carry a significant
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Parametrial adipose tissue characteristics
Figure 1: White adiposity characteristics in normal and PCOS adult rats. Representative images of parametrial adipose tissue pads stained
with hematoxylin and eosin (a). Lower 3-diagram panel showing data from parametrial pad adipocyte (in left-right order) size, mass, and
in vitro leptin secretion. Finally, parametrial pad adiponectin protein content (Western blot) (b). Magnification ×400; scale bars: 50μm.
∗P < 0 05 versus respective normal-group values (adapted from Alzamendi et al. [34]).
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and type 2 diabetes and an intrinsic prooxidant state
resulting from imbalance between excessive oxidant produc-
tion in the presence of limited antioxidant defence. MS
comprises many risk factors for cardiovascular disease
including hyperinsulinemia, glucose intolerance, dyslipid-
emia, hyperadiposity/obesity, and elevated blood pressure.
MS prevalence ranges from 15 to 30% depending on the
world region considered [46, 47]. A 1.5- to 2.5-fold increase
in cardiovascular mortality occurs whenMS is present, repre-
senting one of the major public health problems at this time.
In the last decade, the understanding of the cellular and
molecular events that contribute to MS development has
increased considerably. One basic function apparently
heavily influenced by obesity and metabolic disease is the
internal timing system [48–50]. The correlation between
increased occurrence of obesity and the ubiquity of modern
social habits, such as light at night, unusual meal times, and
irregular sleep/wake schedules, all encompassed by a “24/7”
lifestyle, strongly suggests that impairment of sleep and
the circadian system is involved in the etiology of MS.
Several clinical surveys have shown increased prevalence
of MS in night-shift workers, indicating that artificial lighting
may contribute to increased prevalence of metabolic
disorders [51–55].
Because melatonin, as a chronobiotic/cytoprotective
agent, has a special place in prevention and treatment of
MS [52–54], its possible therapeutic utility in PCOS has been
considered. Low levels of melatonin at night have been linked
to metabolic abnormalities such as insulin resistance and
type 2 diabetes mellitus. Moreover, the suppression of
nocturnal melatonin by light exposure at night has been
associated with several pathologies comprising MS [56–58].
Melatonin is measurable in human preovulatory
follicular fluid and may play a role in regulating ovarian ste-
roidogenesis, folliculogenesis, and oocyte maturation [59].
Melatonin can protect follicles against oxidative stress and
may rescue follicles from atresia, thereby promoting correct
follicular maturation and, ultimately, ovulation [60].
Table 1 summarizes results supporting a therapeutic role
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Figure 2: White adipose tissue (WAT) and inflammation: endocrine-metabolic consequences. A combination of genetic background and
endogenous androgen excess could induce WAT mass hypertrophic expansion associated with macrophage infiltration, leading to an
abnormal pattern of adipokine secretion. Enhanced WAT-derived leptin release, in turn, impairs tissue sensitivity to insulin (insulin
resistance (IR)). Prolonged hyperleptinemia could induce long-form leptin receptor (ObRb) downregulation, namely, at the
pancreatic (β- and α-cell) level, thus impairing its negative feedback mechanism on insulin (and glucagon) secretion; moreover,
increased release of proinflammatory signals (TNF, IL-1, IL-6, and C-reactive protein (CRP), among others) worsens several functions. In
fact, overall WAT dysfunction promotes multiple endocrine-metabolic dysfunctions, such as generalized IR, enhanced reticulum
endoplasmic oxidative stress (REOS), enhanced lipolytic activity, cell hypoxia, and apoptosis. These alterations, in turn, affect multiple
peripheral organs, namely, liver, muscle, endocrine pancreas, and endothelium functions. FFA: free fatty acid; JUNK: Janus kinase; NF-κB:
nuclear factor-κB; HGP: hepatic glucose production; NAFLD: nonalcoholic fatty liver disease; NASH: nonalcoholic steatohepatitis; DMT2:
diabetes mellitus type 2 (adapted from Pagano et al. [108]).
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melatonin levels after pinealectomy induces the development
of some characteristics of PCOS. Published data indicate that
the direct effect of melatonin on follicular steroid production
is complex and may depend on the cell type (theca cell or
granulose cell), duration of treatment (acute or long-term
response), experimental model (cell culture or follicle
culture), species, and dose [61]. Melatonin may directly
suppress follicular (thecal) steroidogenesis at an early stage
in the steroid synthesis pathway by blocking the expression
of steroidogenic acute regulatory protein, which facilitates
translocation of cholesterol across the intermembrane space
into the inner membrane to be cleaved into pregnenolone.
Treatment of rats with melatonin can reduce obesity, type 2
diabetes, and hepatic steatosis [62, 63], and in several animal
models of hyperadiposity melatonin injection normalized
most observed alterations and corrected the altered biochem-
ical proinflammatory profile.
A significantly higher excretion of 6-sulfatoxymelatonin,
the major excretory metabolite of melatonin, was reported in
patients with PCOS [64–66]. Other studies later described
higher serum melatonin concentrations associated with
ovarian intrafollicular deficiency of melatonin in patients
Table 1: Relevance of melatonin in PCOS.
Observation Reference/s
Significantly higher secretion of melatonin in PCOS women [64–68]
Family association study between melatonin receptor gene polymorphisms and PCOS [77–79]
Supplementation of in vitro culture medium with melatonin improved IVF outcome in PCOS [80]
Melatonin and myo-inositol enhanced, synergistically, oocyte, and embryo quality and
improved in vitro fertilization of patients with PCOS
[81]
Melatonin treatment restores menstrual cyclicity in women with PCOS [82]
Treatment of preinvasive endometrial cancer in women with PCOS using female sexual hormones in
combination with melatonin, antidiabetic, antidopaminergic, and antiserotonin therapy favorably influenced
female sexual hormone profile and lipid metabolism and caused the restoration of normal endometrium
[83]
Melatonin treatment ameliorated oxidative stress and inflammatory parameters of obese women [84]
Reduced fat mass and increased lean mass in response to 1 year of melatonin treatment in postmenopausal women [85]


























Figure 3: Follicular developmental stage of the ovaries obtained from normal and PCOS adult rats (a). Values are expressed in percentages.
∗P < 0 05 versus normal-group values. Representative images (b) of the ovaries from normal (A, C, and E) and PCOS (B, D, and F) adult rats
showing ovarian structures at different magnifications: (A) and (B): 10x (bars: 100μm); (C) and (D): 20x (scale bars: 50μm); (E) and (F): 40x
(scale bars: 25μm). CL: corpus luteum; IG: interstitial glands; FC: follicular cyst; G: granulosa; TI: theca interna; Ov: ovocyte (adapted from
Ongaro et al. [45]).
5International Journal of Endocrinology
with PCOS [67, 68]. Regardless of that, the intrafollicular
melatonin concentrations are lower in PCOS than in controls
[61]. The high circulating levels of melatonin in PCOS may
be a feedback response to the deficient levels of melatonin
in the ovary [61]. High levels of melatonin in the follicular
fluid is essential for follicle growth, ovulation, and oocyte
quality, whereas reduced follicular melatonin concentra-
tions may be responsible for anovulation and poor oocyte
quality in PCOS.
Melatonin communicates nightly timing cues through
activation of two G protein-coupled receptors, that is,
melatonin receptor 1 (MT1) and melatonin receptor 2
(MT2) [68]. Both MT1 andMT2 have been shown to activate
several signalling pathways, most notably the Gi/cAMP
and Gq/phospholipase C/Ca2+ pathways. These receptors
are expressed in many different peripheral tissues such
as the ovary and modulate multiple aspects of human
physiology [69].
Genome-wide association studies have shown that
polymorphisms in the genes encoding human melatonin
receptors (MTNR1A and MTNR1B) are involved in the
pathogenesis of type 2 diabetes mellitus [70–76]. By rese-
quencing the coding region of the MTNR1B gene coding
for the MT2 receptor, variants have been identified and
functionally characterized. Corresponding mutants with
impaired receptor signalling are strongly associated with
diabetic risk, indicating that loss of melatonin receptor
function is positively associated with disease risk.
Variants in MTNR1B (MT2) have been linked to
impairments in both insulin secretion and increased fasting
glucose levels, and variants in MTNR1A (MT1) have been
shown to be associated with increased risk of developing
PCOS [77–80]. Polymorphisms rs2119882 in the MTNR1A
gene and rs10830963 in the MTNR1B gene were proposed
to have a common causative role in the pathogenesis of
PCOS. However, in a recent study to investigate whether an
association exists between these two single-nucleotide
polymorphism variants and PCOS, an association was
detected only between rs2119882 in the MTNR1A gene and
PCOS [77]. Collectively, genetic data provide a basis for
further studies of the MTNR gene in the etiology of PCOS.
Melatonin may directly affect ovarian function: it is
concentrated in human ovarian follicles relative to the level
in plasma, and it alters granulosa cell steroidogenesis and
follicular function in humans [60]. However, only a few
studies have been published on melatonin potential as a
therapeutic agent in humans in the PCOS.
Two of them relate to improvement of in vitro fertiliza-
tion of patients with PCOS. The supplementation of
in vitro culture medium with melatonin improved in vitro
fertilization outcome in PCOS [81] while melatonin and
myo-inositol enhanced, synergistically, oocyte and embryo
quality and improved in vitro fertilization of patients with
PCOS [82]. These findings suggest that the addition of
melatonin to in vitro fertilization media may improve the
cytoplasmic maturation of immature oocytes.
In an open-label study including 40 normal-weight
women with PCOS, ultrasound pelvic examinations, hirsut-
ism score evaluation, hormone profile assays, oral glucose
tolerance test, and lipid profile at baseline and after a
6-month administration of 2mg fast release melatonin
po daily at bedtime were recorded [83]. Melatonin treatment
significantly decreased serum androgen and 17α-hydroxy-
progesterone levels and augmented serum FSH and anti-
Mullerian hormone serum levels. Almost 95% of participants
experienced an amelioration of menstrual cycle disruption.
No significant changes occurred in glucoinsulinemic and
lipid parameters after treatment except a significant decrease
in low-density lipoprotein cholesterol.
Treatment of preinvasive endometrial cancer in women
with PCOS using melatonin in combination with female
sexual hormones and antidiabetic, antidopaminergic, and
antiserotoninergic therapy favorably influenced female
sexual hormone profile and lipid metabolism and caused
restoration of normal endometrium [84]. Indeed, melatonin
treatment ameliorated oxidative stress and inflammatory
parameters of obese women [85] and reduced fat mass and
increased lean mass in postmenopausal women [86].
Therefore, the data in Table 1 agree with many studies
now supporting the beneficial role of melatonin in patients
with MS. Melatonin treatment ameliorates MS in obese
patients [87, 88] as well as in bipolar and schizophrenic
patients after treatment with second-generation antipsy-
chotics [89–91]. Melatonin administration normalizes MS
in elderly hypertensive patients [92] and improves enzyme
profile in patients with alcoholic liver steatosis [88, 89]. Using
melatonin and zinc acetate, when employed alone or in
combination with metformin, improved glycemic control in
type 2 diabetic patients [93], and an inverse relationship
between urinary 6-sulfatoxymelatonin excretion and insulin
levels versus insulin resistance was reported in healthy
women in the Nurses’ Health Study cohort [94]. It must be
noted however that there are results that deny the capacity
of melatonin to improve glucose tolerance and to reduce
insulin resistance in humans. Melatonin administration
decreased glucose tolerance, already in nondiabetic young
individuals [95–97]. Although the results summarized in
Table 1 suggest that melatonin therapy may be beneficial
for patients with PCOS, more studies are obviously needed
to evaluate an appropriate time/duration of treatment/dose
relationship for administration of melatonin.
4. Concluding Remarks
Many metabolic-reproductive alterations associated with
PCOS are closely dependent on WAT dysfunction, particu-
larly at the VAT pad level. However, the increase in VAT
pad mass per se is not an unequivocal indication of VAT dys-
function, whereas development of enlarged local adipocytes
is indeed a key factor. Androgen excess is able to induce an
imbalance between white adipocyte hypertrophy and hyper-
plasia, towards enlarged (IR) adipocytes and consequent
VAT dysfunction and inflammation. Many factors regulate
normal VAT mass expansion. In this review, we ponder
the influence of testosterone, a sex steroid hormone in
excess (hyperandrogenemia and/or hyperandrogenism) in
PCOS phenotypes. Factors modulating adipogenesis/
inflammation could become new therapeutic targets to
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counteract endocrine-metabolic-reproductive dysfunction,
favoring healthy WAT mass expansion and counteracting
hypertrophic adiposity-associated dysfunctions.
According to the Rotterdam ESHRE/ASRM-Sponsored
PCOS Consensus Workshop Group, it was concluded that
PCOS is a syndrome of ovarian dysfunction along with the
cardinal feature hyperandrogenism and polycystic ovary
(PCO) morphology [1]. However, because PCOS remains a
syndrome, not a single diagnostic criterion is sufficient for
clinical diagnosis. There are many other clinical manifesta-
tions that may be included, such as menstrual irregularities,
signs of androgen excess, obesity, insulin resistance, elevated
serum levels of LH, increased risk of type 2 diabetes [98], and
cardiovascular events [99]. Clinical management of PCOS
should include rigorous lifestyle modifications, insulin ther-
apy, and drug treatments that promote insulin sensitization
(such as metformin) and insulin secretion (such as glibencla-
mide), dipeptidyl peptidase-4 inhibitors, sodium glucose
cotransporter 2 inhibitors [100], and antihyperlipidemic
therapy [101]. In general, these approaches are designed to
manage symptoms of insulin resistance/β-cell dysfunction
and dyslipidemia and are used either alone or in combina-
tion. Drug therapies are expensive worldwide and in some
cases have been associated with adverse secondary events
including pancreatitis, hypoglycemia, and osteoporosis
[102, 103]. Therefore, a need remains for new and cost-
effective pharmacotherapies for diabetes presenting limited
additional health risks.
Although overweight/obesity is preventable, its preva-
lence is continuously increasing worldwide, and because it
is frequently associated with other cardiovascular risk factors
and high mortality, obesity has become an important public
health problem and a heavy socioeconomic burden for
society as a whole. Environmental factors, hormone excess
(e.g., androgen), or stressors of so-called contemporary
“24/7” societies have pronounced effects on metabolism pro-
ducing circadian clock disruption. Further, people whose
work involves irregular time schedules and forced exposure
to bright light at night (night/shift workers) show significant
disruptions in sleep architecture and increased prevalence of
MS. These lines of evidence indicate that the body’s system
fails to adjust properly to environmental and/or stressor
changes disrupting overall metabolic homeostasis.
Melatonin may provide an innovative strategy in PCOS
by combining its chronobiotic effect on circadian rhythm
with cytoprotective properties. Indeed, melatonin protects
against several MS comorbidities in PCOS, such as diabetes
and concomitant oxy-radical mediated damage, inflamma-
tion, microvascular disease, atherothrombotic risk, and ovary
dysfunction. Melatonin may therefore have a place from
the initial phases of PCOS treatment. Its high safety profile
and reduced toxicity distinguishes it from many pharma-
ceutical agents used in PCOS patients (Figure 4). In
conclusion, an appropriately classical pharmacological
treatment combined with melatonin should be considered
in PCOS individuals to restore endocrine-metabolic and
reproductive functions.
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Figure 4: Effect of melatonin in PCOS associated with metabolic syndrome. Melatonin normalizes high blood pressure (BP) and circulating
indexes of inflammation. It also improves insulin sensitivity and restores disrupted circadian rhythms. Melatonin directly affects ovarian
function: it is concentrated in human ovarian follicles in relation to the level in plasma, and it improves granulosa cell steroidogenesis and
follicular function in humans (adapted from Reiter et al. [61]).
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